1. Home
  2. ENPH vs BLLN Comparison

ENPH vs BLLN Comparison

Compare ENPH & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enphase Energy Inc.

ENPH

Enphase Energy Inc.

HOLD

Current Price

$45.14

Market Cap

5.9B

Sector

Technology

ML Signal

HOLD

Logo BillionToOne Inc.

BLLN

BillionToOne Inc.

HOLD

Current Price

$125.65

Market Cap

5.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENPH
BLLN
Founded
2006
2016
Country
United States
United States
Employees
2872
713
Industry
Semiconductors
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
5.2B
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
ENPH
BLLN
Price
$45.14
$125.65
Analyst Decision
Hold
Buy
Analyst Count
23
7
Target Price
$41.30
$126.71
AVG Volume (30 Days)
6.4M
711.6K
Earning Date
04-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
72.00
N/A
EPS
N/A
N/A
Revenue
$1,472,985,000.00
N/A
Revenue This Year
N/A
$46.29
Revenue Next Year
$9.81
$30.14
P/E Ratio
N/A
N/A
Revenue Growth
10.72
N/A
52 Week Low
$25.78
$61.96
52 Week High
$73.74
$138.70

Technical Indicators

Market Signals
Indicator
ENPH
BLLN
Relative Strength Index (RSI) 43.31 65.63
Support Level $41.24 $79.07
Resistance Level $46.87 $138.70
Average True Range (ATR) 3.66 6.68
MACD -0.53 0.68
Stochastic Oscillator 29.38 90.04

Price Performance

Historical Comparison
ENPH
BLLN

About ENPH Enphase Energy Inc.

Enphase Energy is a global energy technology company. It delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Enphase derives a majority of revenue from the United States.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: